文献速递临床免疫质量管理与危急值

三轮国家室间质评揭示抗SARS-CoV-2抗体定量不一致与感染阶段相关

Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage.
PubMed 文献 · Clin Chem Lab Med · 2023-02-10

该研究分析三轮国家室间质评中46、50、44家实验室对SARS-CoV-2康复者、急性感染者及疫苗接种者样本的抗棘突抗体定量结果。发现同一试剂盒重复性佳,但不同试剂盒间BAU/mL比值随感染阶段而异,不支持通用转换因子。

要点

  • 不同免疫试剂盒测得的BAU/mL比值在疫苗接种、既往感染和急性感染间存在差异。
  • 仅使用同一试剂盒时,不同实验室的BAU/mL结果才可互换。
  • 不同试剂盒间BAU/mL定量比值高度可变,反对使用通用转换因子。

核心结论

  • 不同免疫试剂盒测得的BAU/mL水平仅在相同试剂盒评估时可跨实验室互换。
  • 不同试剂盒间BAU/mL定量比值高度可变且随感染阶段不同,反对使用通用转换因子。

研究设计与样本

  • 研究分析三轮国家室间质评中46、50、44家参与实验室报告的结果。
  • 样本来自SARS-CoV-2康复者、急性感染者及疫苗接种者,包括Omicron变异株原发和突破性感染后样本。

主要发现

  • 参与实验室最常用的三种免疫试剂盒在相同样本重复检测中表现出低批内和实验室间变异,重复性极佳。
  • 所有样本的不同试剂盒间变异非常高。
  • 不同免疫试剂盒定量的BAU/mL比值在所有样本中不相等,且在疫苗接种、既往感染和急性感染(包括Omicron原发感染)间存在差异。
  • 疫苗接种个体的抗体动力学测量强烈依赖于所用免疫试剂盒。

关键数值与推荐

  • 不同免疫试剂盒间BAU/mL定量比值高度可变,不支持使用通用试剂盒间转换因子。

临床怎么用

  • 解读BAU/mL结果时需注明所用免疫试剂盒,不同试剂盒结果不可直接互换。
  • 不宜使用通用转换因子在不同免疫试剂盒间换算BAU/mL水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The WHO's standardized measuring unit, "binding antibody units per milliliter (BAU/mL)," should allow the harmonization of quantitative results by different commercial Anti-SARS-CoV-2 immunoassays. However, multiple studies demonstrate inter-assay discrepancies. The antigenic changes of the Omicron variant affect the performance of Spike-specific immunoassays. This study evaluated the variation of quantitative Anti-SARS-CoV-2-Spike antibody measurements among 46, 50, and 44 laboratories in three rounds of a national external quality assessment (EQA) prior to and after the emergence of the Omicron variant in a diagnostic near-to-real-life setting. METHODS: We analyzed results reported by the EQA participant laboratories from single and sequential samples from SARS-CoV-2 convalescent, acutely infected, and vaccinated individuals, including samples obtained after primary and breakthrough infections with the Omicron variant. RESULTS: The three immunoassays most commonly used by the participants displayed a low intra-assay and inter-laboratory variation with excellent reproducibility using identical samples sent to the participants in duplicates. In contrast, the inter-assay variation was very high with all samples. Notably, the ratios of BAU/mL levels quantified by different immunoassays were not equal among all samples but differed between vaccination, past, and acute infection, including primary infection with the Omicron variant. The antibody kinetics measured in vaccinated individuals strongly depended on the applied immunoassay. CONCLUSIONS: Measured BAU/mL levels are only inter-changeable among different laboratories when the same assay was used for their assessment. Highly variable ratios of BAU/mL quantifications among different immunoassays and infection stages argue against the usage of universal inter-assay conversion factors.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Buchta C, Springer D, Jovanovic J, et al. Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage. Clin Chem Lab Med. 2023. PMID: 36756735. doi:10.1515/cclm-2022-1161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。